05.06.20: Not intended for U.S. and UK Media

Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failureRegulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine (1)mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news